WKYMVm Peptide Analogues for Stable FPR-Mediated MS Immune Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MS therapeutics have limited efficacy, particularly for RRMS, and existing treatments like Ocrevus and Kesimpta come with high costs and side effects, necessitating new therapeutic approaches that target the complex immune and nervous networks involved in MS pathology, especially the inflammatory response at the blood-brain barrier.
Innovation Solution
Development of WKYMVm peptide analogues with enhanced stability and specificity for FPR receptors, increasing neutrophil activity and regulating immune cell functions to modulate immune responses, including increasing IgA+ B cell production and inhibiting inflammatory cell accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MS therapeutics (Ocrevus, Kesimpta) are used to treat multiple sclerosis, then immune regulation effects are achieved, but treatment costs become excessively high and side effects occur
Solution Approach 1:
The patent employs a short-peptide structure (WKYMVm and analogues) that can be administered repeatedly at low cost, replacing expensive long-term therapies like Ocrevus and Kesimpta. The peptide's small size and simplified structure enable cost-effective production while maintaining therapeutic efficacy through multiple administrations.
Solution Approach 2:
The invention extracts and isolates the specific FPR agonist activity from complex immunomodulatory mechanisms. By focusing on a single peptide sequence that specifically targets FPR receptors, the patent simplifies the therapeutic approach while avoiding the complex side effect profiles of broader immunosuppressants.
2Duration of action of stationary object
If peptide stability is increased through structural modification, then in vivo half-life is extended, but peptide structure complexity increases
Solution Approach 1:
The patent systematically modifies peptide parameters including amino acid substitutions (e.g., WKYMVm to various analogues), C-terminal modifications (amide to acid), and N-terminal modifications (acetylation). These parameter changes extend in vivo half-life while maintaining relatively simple peptide structures that are still easier to produce than larger biologic molecules.
Solution Approach 2:
The invention creates composite peptide structures by combining the core WKYMVm sequence with various stabilizing modifications at terminal positions. These composite structures achieve extended stability through synergistic effects of the core sequence and modifying groups without requiring complete structural redesign.
3Reliability
If FPR receptor specificity is enhanced through peptide optimization, then immune cell activation is improved, but peptide selectivity requirements become more stringent
Solution Approach 1:
The patent optimizes specific local regions of the peptide sequence, particularly the C-terminal region (YMVm and variants), to enhance FPR binding affinity and selectivity. By focusing optimization on key residues rather than the entire sequence, the invention achieves high receptor specificity while maintaining manufacturing feasibility.
Solution Approach 2:
The invention develops a series of peptide analogues with gradually optimized FPR specificity, allowing dynamic selection of the most appropriate peptide variant for different therapeutic indications. This dynamic approach enables tuning of selectivity requirements based on specific clinical needs rather than requiring maximum precision in all cases.
Data Source
AI summary
The present invention relates to a WKYMVm peptide analogue and uses thereof, and the WKYMVm peptide analogues have increased stability due to an increased in vivo degradation half-life, enhance activity of neutrophils as a formylpeptide receptor agonist, and regulate the activity of immune cells mediating pathology of multiple sclerosis so that they can be effectively used for enhancing immunity or preventing or treating multiple sclerosis.